Literature DB >> 14709781

The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects.

Mukut Sharma1, Ram Sharma, Ellen T McCarthy, Virginia J Savin.   

Abstract

Focal segmental glomerulosclerosis (FSGS) is characterized by steroid resistant nephrotic syndrome and progression to end-stage renal disease. Proteinuria in certain patients with FSGS may be caused by a circulating factor (FSGS permeability factor [FSPF]). The current report documents the biochemical characteristics and the biological and molecular effects of 70% ammonium sulfate supernatant of plasma from patients with recurrence of FSGS after transplantation (FSGS 70% supernatant). FS permeability activity, defined as the capacity of plasma from patients with FSGS to increase albumin permeability (P(alb)) of isolated glomeruli, was assessed in vitro. Permeability activity was not affected by lyophilization. FSPF bound strongly to matrices containing Mono-Q anion exchanger or protein A. It eluted from matrix-bound Cibacron blue F3GA over a wide range of salt concentrations, indicating a potential binding with other proteins, such as albumin. FSPF caused a maximal increase in P(alb) within 2 mins of incubation in vitro. Cellular proteins isolated from glomeruli with increased P(alb) showed decreased tyrosine phosphorylation of focal adhesion kinase, paxillin, and other proteins. Tyrosine phosphatase ]inhibition prevented the increase in P(alb). Intravenous administration of as little as 3 mg protein in FSGS 70% supernatant increased P(alb), while 9 mg or more were required to produce proteinuria. We conclude that FSPF is a low-molecular-weight protein, carries an anionic charge, and binds to protein A. Effects of FSPF on the glomerular permeability barrier are rapid and dose dependent and involve signaling through altered phosphorylation of cellular proteins. Identification of these biochemical and biological characteristics may be used to design strategies for removing FSPF from circulation and for purification and identification of this factor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14709781     DOI: 10.1177/153537020422900111

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  24 in total

1.  Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier.

Authors:  Mukut Sharma; Jianping Zhou; Jean-François Gauchat; Ram Sharma; Ellen T McCarthy; Tarak Srivastava; Virginia J Savin
Journal:  Transl Res       Date:  2015-03-16       Impact factor: 7.012

2.  The anti-CD40 auto-antibody: a biomarker or a factor for the permeability of recurrent focal segmental glomerulosclerosis?

Authors:  Séverine Beaudreuil; Hans Kristian Lorenzo; Antoine Durrbach
Journal:  Ann Transl Med       Date:  2015-06

3.  Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.

Authors:  Furong Li; Chunxia Zheng; Yongzhong Zhong; Caihong Zeng; Feng Xu; Ru Yin; Qi Jiang; Minlin Zhou; Zhihong Liu
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-15       Impact factor: 8.237

4.  Expression of immunoglobulin E-dependent histamine-releasing factor in idiopathic nephrotic syndrome of childhood.

Authors:  S Toyabe; U Kaneko; M Hara; M Uchiyama
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

5.  Recurrent focal segmental glomerulosclerosis after kidney transplantation.

Authors:  Rebecca Trachtman; Simranjeet S Sran; Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2015-02-19       Impact factor: 3.714

6.  ADMA injures the glomerular filtration barrier: role of nitric oxide and superoxide.

Authors:  Mukut Sharma; Zongmin Zhou; Hiroto Miura; Andreas Papapetropoulos; Ellen T McCarthy; Ram Sharma; Virginia J Savin; Elias A Lianos
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-18

Review 7.  Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis : an update of treatment options for children.

Authors:  Jochen H H Ehrich; Lars Pape; Mario Schiffer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

8.  Recurrence of proteinuria following renal transplantation in congenital nephrotic syndrome of the Finnish type.

Authors:  Tarak Srivastava; Robert E Garola; Marjo Kestila; Karl Tryggvason; Vesa Ruotsalainen; Mukut Sharma; Virginia J Savin; Hannu Jalanko; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2006-03-04       Impact factor: 3.714

9.  8,9-Epoxyeicosatrienoic acid protects the glomerular filtration barrier.

Authors:  Mukut Sharma; Ellen T McCarthy; D Sudarshan Reddy; Paresh K Patel; Virginia J Savin; Meetha Medhora; John R Falck
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-06       Impact factor: 3.072

10.  Rituximab for refractory focal segmental glomerulosclerosis.

Authors:  Makiko Nakayama; Koichi Kamei; Kandai Nozu; Kentaro Matsuoka; Atsuko Nakagawa; Mayumi Sako; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2007-11-01       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.